Protagonist Therapeutics, Inc. (PTGX) is a Biotechnology company in the Healthcare sector, currently trading at $104.72. It has a SharesGrow Score of 67/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PTGX = $28.60 (-72.7% from the current price, the stock appears overvalued). Analyst consensus target is PTGX = $114 (+8.5% upside).
Valuation: PTGX trades at a trailing Price-to-Earnings (P/E) of -50.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.42.
Financials: revenue is $46M, +220.1%/yr average growth. Net income is $130M (loss), growing at +112.4%/yr. Net profit margin is -282.8% (negative). Gross margin is 97.3% (+1.2 pp trend).
Balance sheet: total debt is $10M against $615M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 12.71 (strong liquidity). Debt-to-assets is 1.5%. Total assets: $670M.
Analyst outlook: 25 / 26 analysts rate PTGX as buy (96%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 88/100 (Pass), Income 10/100 (Fail).
